Chronic kidney disease (ckd) data
Table of Contents
Description
A randomized study was conducted to compare Eplerenone(n= 23) with standard treatment (n= 22) in patients with Chronic Kidney Disease (Boesby et al., 2013). The studied outcome included pulse wave velocity (pwv) and augmentation index (aix) measured at baseline and after 12 and 24 weeks of treatment.
Variables
| Variable | Explanation (Unit) |
|---|---|
| group | Treatment group: 1 if eplerenone, 0 if control |
| sex | Sex: 1 for male, 0 for female |
| age | Age |
| pwv0 | Pulse wave velocity at baseline (m/s) |
| pwv12 | Pulse wave velocity at 12 weeks (m/s) |
| pwv24 | Pulse wave velocity at 24 weeks (m/s) |
| aix0 | Augmentation index at baseline (%) |
| aix12 | Augmentation index at 12 weeks (%) |
| aix24 | Augmentation index at 24 weeks (%) |
Load data into R
load(url("http://paulblanche.com/files/ckd.rda")) head(ckd)
References
Boesby, L., Elung-Jensen, T., Strandgaard, S., & Kamper, A. L. (2013). Eplerenone attenuates pulse wave reflection in chronic kidney disease stage 3–4-A randomized controlled study. PLoS One, 8(5), e64549.